Search
Compass Therapeutics Inc.
CMPXAdd to Watchlist
2.020USD
-0.030-1.46%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
363.78MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Compass Therapeutics Inc. is 8.71, ranking 74 out of 389 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 30.00 and a low of 7.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
8.818
Target Price
+330.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Compass Therapeutics Inc.
CMPX
14
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Compass Therapeutics Inc.'s price target?
Analysts forecast that Compass Therapeutics Inc.'s price target is USD 10.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 7.00.
How have Compass Therapeutics Inc.CMPX's recent earnings per share performed?
The market expectation was USD -0.10, while Compass Therapeutics Inc.CMPX's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for Compass Therapeutics Inc.?
Based on the ratings of Compass Therapeutics Inc.'s stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
